Quidel Corp Stock: price and insider trades · United States

QuidelOrtho Corporation (Nasdaq: QDEL) is a U.S.-listed company traded on the NASDAQ market in the United States. The company was created in 2022 through the combination of Quidel and Ortho Clinical Diagnostics, while Quidel’s operating history dates back to 1979. Its world headquarters is in San Diego, California, which places the company in one of the most established U.S. medtech and diagnostics hubs. For investors, QDEL is best viewed as a diagnostic-testing franchise with defensive end markets, but one that remains exposed to respiratory seasonality, hospital utilization trends, and laboratory spending patterns.

QuidelOrtho develops and commercializes in vitro diagnostic solutions spanning point-of-care testing, clinical laboratories, and transfusion medicine. Its core portfolio includes the SOFIA platform for automated point-of-care immunoassays, QuickVue rapid lateral-flow tests, the TRIAGE system for quick diagnostic results at the point of care, and the VITROS and ORTHO product families used in laboratory testing and immunohematology. The company also offers molecular testing solutions and related reagents. According to company materials, it serves customers in more than 140 countries and territories, giving it a broad commercial footprint and meaningful diversification across healthcare settings and geographies. That reach is strategically important because the business is not dependent on a single product line or a single end market.